SG Americas Securities
CBIO

SG Americas Securities’s Crescent Biopharma CBIO Stock Holding History

SG Americas Securities’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-188
Closed -$56K – 3024
2024
Q1 		$56K Buy
+188
New +$56.2K ﹤0.01% 2730
2021
Q1 		– Sell
-147
Closed -$55K – 3377
2020
Q4 		$55K Buy
+147
New +$51.5K ﹤0.01% 3131
2020
Q3 		– Sell
-185
Closed -$70K – 2981
2020
Q2 		$70K Buy
185
+57
+45% +$16.1K ﹤0.01% 3469
2020
Q1 		$29K Buy
+128
New +$48.9K ﹤0.01% 3254
2018
Q1 		– Sell
-62
Closed -$103K – 3354
2017
Q4 		$103K Buy
+62
New +$82K ﹤0.01% 2842

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities's CBIO Position: Q2 2024 in Review

SG Americas Securities sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 188 shares — an estimated $56K sold.

SG Americas Securities first reported a position in CBIO in Q4 2017 and held it in 5 quarters. The position peaked at $103K in Q4 2017. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • SG Americas Securities reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 188 Crescent Biopharma shares in Q2 2024, an estimated $56K.
  • SG Americas Securities first reported a position in Crescent Biopharma in Q4 2017 and held it in 5 quarters.
  • SG Americas Securities's Crescent Biopharma position peaked at $103K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.